ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. ProBiotix Health’s cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (“LP-LDL®), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.
ProBiotix Health plc
Developer of probiotics and probiotic products
Company information
Company:
Public
Fund:
EIS Portfolio Service, Growth Capital VCT
Sector:
Biotech
Status:
Current
Investment Date:
03/2022
You might also be interested in...
Provider of engineered composite material kits to the aerospace industry